Literature DB >> 24867258

Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma.

Jun Sato1, Yoshimasa Kitagawa, Yutaka Yamazaki, Hironobu Hata, Takuya Asaka, Masaaki Miyakoshi, Shozo Okamoto, Tohru Shiga, Masanobu Shindoh, Yuji Kuge, Nagara Tamaki.   

Abstract

PURPOSE: Hypoxia, a prognostic factor in many types of cancer, can be detected by (18)F-fluoromisonidazole (FMISO) positron emission tomography (PET). It is unclear whether hypoxia reflects the response to chemotherapy in patients with oral squamous cell carcinoma (OSCC). The correlations of FMISO-PET and FDG-PET with histological response to preoperative chemotherapy were therefore assessed in patients with OSCC.
METHODS: This study enrolled 22 patients with OSCC undergoing preoperative chemotherapy. The T-stages were T2 in 6 patients, T3 in 3, and T4a in 13, and the N-stages were N0 in 14 patients, N1 in 3, and N2 in 5. Each patient was evaluated by both FMISO-PET and FDG-PET before surgery, and the maximum standardized uptake value (SUVmax) of FDG- and FMISO-PET and tumor-muscle ratio (TMR) of FMISO-PET were measured. The threshold for the hypoxic volume based on TMR was set at 1.25. The histological response to preoperative chemotherapy was evaluated using operative materials.
RESULTS: FMISO-PET and FDG-PET detected uptake by primary OSCCs in 15 (68%) and 21 (95%) patients, respectively, and median SUVmaxs of FMISO- and FDG-PET in the primary site were 2.0 (range, 1.3-3.5) and 16.0 (range, 1.0-32.2), respectively. The median of FMISO TMR was 1.5 (range, 0.99-2.96). There were five cases whose FMISO TMR was less than 1.25. Histological evaluation showed good response to preoperative chemotherapy in 7 patients (32%) and poor response in 15 (68%). Good response was significantly more prevalent in patients with negative than positive FMISO uptake (P < 0.001) and without the hypoxic area evaluated by FMISO-PET TMR (P = 0.04), whereas FDG uptake was not significantly correlated with response to chemotherapy response. Multivariate logistic regression analysis showed that FMISO uptake was an independent significant predictor of response to preoperative chemotherapy (P = 0.03, odds ratio = 0.06, 95% confidence interval = 0.004-0.759).
CONCLUSIONS: An advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with OSCC was observed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24867258     DOI: 10.1007/s00259-014-2810-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  51 in total

1.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole.

Authors:  W J Koh; J S Rasey; M L Evans; J R Grierson; T K Lewellen; M M Graham; K A Krohn; T W Griffin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.

Authors:  Yoshimasa Kitagawa; Kazuo Sano; Sadahiko Nishizawa; Mikiko Nakamura; Toshiyuki Ogasawara; Norihiro Sadato; Yoshiharu Yonekura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10-26       Impact factor: 9.236

3.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients.

Authors:  J S Rasey; W J Koh; M L Evans; L M Peterson; T K Lewellen; M M Graham; K A Krohn
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-09-01       Impact factor: 7.038

4.  FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms.

Authors:  Y Kitagawa; N Sadato; H Azuma; T Ogasawara; M Yoshida; Y Ishii; Y Yonekura
Journal:  J Nucl Med       Date:  1999-07       Impact factor: 10.057

5.  High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.

Authors:  Shozo Okamoto; Tohru Shiga; Koichi Yasuda; Yoichi M Ito; Keiichi Magota; Katsuhiko Kasai; Yuji Kuge; Hiroki Shirato; Nagara Tamaki
Journal:  J Nucl Med       Date:  2013-01-15       Impact factor: 10.057

6.  Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study.

Authors:  Mei Tian; Hong Zhang; Yoshiki Nakasone; Kenji Mogi; Keigo Endo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-10       Impact factor: 9.236

7.  Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.

Authors:  Xianrang Song; Xianxi Liu; Weiling Chi; Yonglei Liu; Ling Wei; Xingwu Wang; Jinming Yu
Journal:  Cancer Chemother Pharmacol       Date:  2006-03-11       Impact factor: 3.333

8.  Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.

Authors:  Douglas S Hawkins; Joseph G Rajendran; Ernest U Conrad; James D Bruckner; Janet F Eary
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

9.  ¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.

Authors:  Chang-Bae Kong; Byung Hyun Byun; Ilhan Lim; Chang Woon Choi; Sang Moo Lim; Won Seok Song; Wan Hyeong Cho; Dae-Geun Jeon; Jae-Soo Koh; Ji Young Yoo; Soo-Yong Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-30       Impact factor: 9.236

10.  Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest.

Authors:  Sayaka Yoshiba; Daisuke Ito; Tatsuhito Nagumo; Tatsuo Shirota; Masashi Hatori; Satoru Shintani
Journal:  Oral Oncol       Date:  2008-08-16       Impact factor: 5.337

View more
  6 in total

Review 1.  F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy.

Authors:  Joseph G Rajendran; Kenneth A Krohn
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

Review 2.  Tumor hypoxia: a new PET imaging biomarker in clinical oncology.

Authors:  Nagara Tamaki; Kenji Hirata
Journal:  Int J Clin Oncol       Date:  2015-11-14       Impact factor: 3.402

Review 3.  Molecular mechanisms of hypoxia in cancer.

Authors:  Amarnath Challapalli; Laurence Carroll; Eric O Aboagye
Journal:  Clin Transl Imaging       Date:  2017-05-11

4.  Semi-quantitative analysis of pre-treatment morphological and intratumoral characteristics using 18F-fluorodeoxyglucose positron-emission tomography as predictors of treatment outcome in nasal and paranasal squamous cell carcinoma.

Authors:  Noriyuki Fujima; Kenji Hirata; Tohru Shiga; Koichi Yasuda; Rikiya Onimaru; Kazuhiko Tsuchiya; Satoshi Kano; Takatsugu Mizumachi; Akihiro Homma; Kohsuke Kudo; Hiroki Shirato
Journal:  Quant Imaging Med Surg       Date:  2018-09

5.  Glucose Metabolism and Its Complicated Relationship with Tumor Growth and Perfusion in Head and Neck Squamous Cell Carcinoma.

Authors:  Noriyuki Fujima; Tomohiro Sakashita; Akihiro Homma; Kenji Hirata; Tohru Shiga; Kohsuke Kudo; Hiroki Shirato
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

6.  Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer.

Authors:  Jeesun Yoon; Seo Young Kang; Kyung-Hun Lee; Gi Jeong Cheon; Do-Youn Oh
Journal:  Cancer Res Treat       Date:  2020-10-22       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.